论文部分内容阅读
新辅助化疗从20世纪80年代开始用于妇科恶性肿瘤临床。研究显示,新辅助化疗可以改善患者状态,消除远处转移病灶,缩小肿瘤直径,改善围手术期结局,提高手术切除率或满意手术的成功率。但新辅助化疗的应用也备受争议,目前最大的局限性在于其未带来明确生存获益。文章就新辅助化疗在妇科不同恶性肿瘤治疗中存在的风险和局限性进行讨论。
Neoadjuvant chemotherapy has been used in gynecologic malignancies since the 1980s. Studies have shown that neoadjuvant chemotherapy can improve the patient’s condition, eliminate distant metastases, reduce tumor diameter, improve perioperative outcomes and improve the rate of surgical resection or satisfactory surgical success. However, the use of neoadjuvant chemotherapy is also debated. The biggest limitation at present is that it does not bring a clear survival benefit. The article discusses the risks and limitations of neoadjuvant chemotherapy in the treatment of different gynecological malignancies.